Drug Search Results
More Filters [+]

Ranolazine

Alternative Names: ranolazine, ranexa, aspruzyo sprinkle
Latest Update: 2024-03-25
Latest Update Note: News Article

Product Description

Ranolazine (Ranexa), a piperazine derivative, is a new antianginal agent approved for the treatment of chronic stable angina pectoris for use as combination therapy when angina is not adequately controlled with other antianginal agents. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16620147/)

Mechanisms of Action: Sodium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ranolazine

Countries in Clinic: China

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Atrial Fibrillation

Phase 2: Angina Pectoris|Angina, Stable|Cardiomyopathy, Hypertrophic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IV-FLEC

P3

Active, not recruiting

Atrial Fibrillation

2023-02-17

Ranolazine microvascular dysfunction HCM

P2

Active, not recruiting

Cardiomyopathy, Hypertrophic

2019-04-06

Ranolazine - AOUPi/001

P2

Active, not recruiting

Angina, Stable

2016-10-24

CTR20131950

P2

Recruiting

Angina, Stable|Angina Pectoris

None

Recent News Events